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REVIEW
Tumor Necrosis Factor–Neutralizing Therapies Improve
Altered Hormone Axes
An Alternative Mode of Antiinflammatory Action
Rainer H. Straub,1 Peter Ha¨rle,1 Piercarlo Sarzi-Puttini,2 and Maurizio Cutolo3
Introduction
In chronic inflammatory diseases such as rheu-
matoid arthritis (RA), ankylosing spondylitis, psoriasis,
Crohn’s disease, and others, tumor necrosis factor
(TNF) neutralization exerts positive disease-ameliorating
effects (1–4). Although significant side effects of anti-
TNF treatment have been reported (5), the use of
anti-TNF strategies has greatly expanded our therapeu-
tic arsenal and started a whole new area of drug
development. In addition, TNF-neutralizing therapies
have extended our understanding of the pathogenetic
role of TNF and downstream molecules such as
interleukin-6 (IL-6) in inflammatory diseases. TNF neu-
tralization has strong direct antiinflammatory effects;
however, such therapy may also support other important
antiinflammatory pathways, such as the hypothalamic–
pituitary–adrenal (HPA) axis, the hypothalamus–
pituitary gland–liver–muscle axis, the hypothalamic–
pituitary–gonadal (HPG) axis, and the hypothalamus–
autonomic nervous system (HANS) axis. Normalization
of the milieu interne would be an important favorable
side effect.
In this review, we summarize the information
regarding how TNF interferes with these neuroendo-
crine axes and how TNF neutralization improves some
of these altered neuroendocrine pathways. From the
present point of view, it seems obvious that blockade of
TNF in chronic inflammatory diseases probably exerts
indirect disease-ameliorating effects by restoring impor-
tant neuroendocrine immune functions.
Loss of adrenal and gonadal androgens
Several independent groups of investigators have
reported markedly decreased serum and urine levels of
androgens such as dehydroepiandrosterone (DHEA),
DHEA sulfate (DHEAS), androstenedione, and testos-
terone in patients with RA (6–11). This finding is
relevant, because androgens exert antiinflammatory ef-
fects in animal models of chronic inflammation and in
patients with RA (for review, see ref. 12). It is thought
that the loss of adrenal and gonadal androgens in
patients with chronic inflammatory diseases supports
continuation of the chronic inflammatory process.
The most important enzymatic step in a cell of
adrenal and gonadal glands responsible for androgen
production is the second step of the P450c17 reaction
(Figure 1 and Table 1). TNF inhibits the reaction of this
double enzyme step in human adrenocortical cells and in
murine Leydig cells (Figure 1 or Table 1) (13,14). In
patients with RA, neutralization of TNF leads to a
significant increase in the level of androstenedione in
1Rainer H. Straub, MD, Peter Ha¨rle, MD: University Hospi-
tal Regensburg, Regensburg, Germany; 2Piercarlo Sarzi-Puttini, MD:
University Hospital L. Sacco, Milan, Italy; 3Maurizio Cutolo, MD:
University of Genoa, Genoa, Italy.
Dr. Sarzi-Puttini has received consultancies (less than
$10,000) from Abbott.
Address correspondence and reprint requests to Rainer H.
Straub, MD, Laboratory of Experimental Rheumatology and
Neuroendocrino-Immunology, Division of Rheumatology, Depart-
ment of Internal Medicine I, University Hospital, 93042 Regensburg,
Germany. E-mail: rainer.straub@klinik.uni-regensburg.de.
Submitted for publication November 22, 2005; accepted in
revised form March 24, 2006.
Arthritis & Rheumatism
An Ofﬁcial Journal of the American College of Rheumatology
www.arthritisrheum.org and www.interscience.wiley.com
2039
relation to that of the precursor hormone 17-
hydroxyprogesterone and, in addition, in relation to
cortisol (15,16). These in vitro and in vivo data indicate
that TNF is an important inhibitor of the second step of
the P450c17 reaction (Figure 1).
Relative decrease of adrenocorticotropic hormone
(ACTH) and cortisol in relation to systemic
inflammation
Although ACTH and cortisol levels seem to be
relatively normal in patients with RA (17), these levels
are low in relation to serum levels of proinflammatory
cytokines. This phenomenon has been called inadequate
ACTH and cortisol secretion relative to inflammation
status (18–24). Tsigos et al reported, in human subjects,
dose-dependent increases in ACTH and cortisol levels in
association with serum IL-6 levels between 0 pg/ml and
250 pg/ml (25), which demonstrated the normal reaction
of the HPA axis on elevated serum cytokine levels. In
RA patients with high serum levels of TNF, serum levels
of cortisol and androgens are normal or lower than
normal, respectively. The reason for this phenomenon is
only partly understood, but continuous stimulation of
the hypothalamus with proinflammatory cytokines such
as TNF or IL-6 in the previously mentioned range
Figure 1. Influence of tumor necrosis factor (TNF) on distinct pathways of steroidogenesis and steroid conversion. Chronically increased serum
levels of TNF diminish pituitary secretion of adrenocorticotropic hormone (ACTH). In adrenocortical cells, TNF inhibits the following enzyme
steps: P450scc, P450c17, P450c21, and P450c11. In the setting of chronic inflammatory diseases, this leads to an observable preponderance of cortisol
at the expense of adrenal or gonadal androgen secretion. In inflamed synovial tissue, TNF inhibits conversion of dehydroepiandrosterone sulfate
(DHEAS) to DHEA, stimulates production of 7-hydroxy-DHEA, and stimulates aromatase. Steroid hormones in red boxes are proinflammatory, and
those in green boxes are antiinflammatory. Cortisone and DHEAS (white boxes) are biologically inactive hormones. Arrows indicate a stimulatory effect.
Lines with a bar at the end indicate an inhibitory influence. StAR steroidogenic acute regulatory protein; ST sulfatase; DSTDHEA sulfotransferase;
5-R  5-reductase; 17-HSD  17-hydroxysteroid dehydrogenase; 3-HSD  3-hydroxysteroid dehydrogenase.
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(0–250 pg/ml of IL-6) results in fast hypothalamic–
pituitary adaptation, leading to unresponsiveness of
these organs (26). In patients with chronic inflammatory
diseases such as RA, cytokine levels remain elevated,
whereas hormone levels become normal (cortisol) or
lower than normal (androgens). Thus, cortisol concen-
trations remain inadequately low in relation to levels of
IL-6 and TNF, and cortisol is unable to decrease pro-
duction of these cytokines. These lower levels of adrenal
hormones are attributable to the direct inhibitory influ-
ence of TNF on expression of the steroidogenic acute
regulatory protein (Table 1) and on ACTH-stimulated
expression of the steroidogenic enzymes P450ssc,
P450c21, and P450c11 in adrenocortical cells (Figure 1
and Table 1) (13).
In a recent study, it was demonstrated that im-
mediately after injection of anti-TNF antibodies, an
increase in ACTH levels was observed in prednisolone-
naive patients with RA (15). ACTH and cortisol levels,
in relation to serum TNF levels, continuously increased
during 12 weeks of anti-TNF therapy (15,16). Further-
more, the ratio of serum cortisol to serum ACTH
decreased during anti-TNF therapy, which indicates
sensitization of ACTH secretion with a relative increase
in ACTH compared with cortisol (15). It is important to
mention that anti-TNF–mediated changes in these hor-
mones are not attributable to changes in serum levels of
cortisol-binding globulin (16). In summary, TNF neu-
tralization leads to an improvement of the HPA axis in
relation to the proinflammatory situation. This normal-
ization of the milieu interne is an additional important
mode of antiinflammatory action.
Intracrinology in synovial tissue
The adrenal and gonadal glands secrete hor-
mones that can be converted to downstream hormones
in nongonadal tissue such as the synovium but also in
breast cells, adipocytes, osteoblasts, hepatocytes, skin
fibroblasts, and others (Table 1). As such, these hor-
mones are prohormones of biologically active sex hor-
mones. For example, in synovial cells, the biologically
inactive DHEAS is converted to the biologically active
DHEA (27), and DHEA is further converted to 7-
hydroxy-DHEA or 16-hydroxy-DHEA (28–30). Other
hormones, such as androstenedione, testosterone, and
17-estradiol, are converted to downstream hormones
(30), which exert quite different effects on the inflam-
matory process (represented by different colors in Fig-
ure 1) (for review, see ref. 31). Conversion of these
prohormones is mediated by available P450-converting
enzymes in nongonadal cells, and this conversion is
largely influenced by cytokines and growth factors (in-
tracrinology) (Table 1).
In patients with RA, it was recently demonstrated
that TNF inhibits conversion of the biologically inactive
androgen DHEAS to the active androgen DHEA in
synovial cells (27). Neutralization of TNF increased the
conversion of DHEAS to DHEA in patients with RA
but not in patients with osteoarthritis (27). This can be
an important antiinflammatory effect, because TNF
neutralization increases the level of the androgen pre-
Table 1. Effects of cytokines and growth factors on distinct P450
enzymes of steroidogenesis in vitro*
P450 enzyme/cell type Cytokine Effect
StAR





Leydig TNF, IFN, IL-1 Inhibition
Ovarian granulosa IL-1 Inhibition
Ovarian theca TGF Stimulation
3-HSD
Leydig TNF, IL-1, bFGF Inhibition
Leydig EGF Stimulation
Ovarian granulosa EGF Stimulation
Nongonadal




Leydig TNF, IFN, IL-1 Inhibition
Leydig TGF1 Inhibition





Ovarian bFGF, IL-6 Stimulation
Ovarian granulosa TGF1 Stimulation
Nongonadal
Breast (epithelial) TNF, IL-6, IL-8 Stimulation
Endometrial cancer IFN Stimulation
Aromatase
Ovarian granulosa TGF1, IL-6 Stimulation
Ovarian granulosa TNF, IL-1, EGF, bFGF Inhibition
Nongonadal
Breast TNF, IL-1, IL-6, IL-11 Stimulation
Adipocyte TNF, IL-6, IL-11 Stimulation
Adipocyte EGF Inhibition
Osteoblast TNF, IL-1, TGF1 Stimulation
Hepatocyte TGF1 Inhibition
Skin fibroblast bFGF Inhibition
* See refs. 69 and 70. The effect of tumor necrosis factor (TNF) is shown
in boldface. StAR  steroidogenic acute regulatory protein; IFN 
interferon-; IL-1  interleukin-1; TGF1  transforming growth factor
1; 3-HSD  3-hydroxysteroid dehydrogenase; bFGF  basic fibro-
blast growth factor; EGF  epidermal growth factor.
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cursor DHEA (Figure 1). Interestingly, serum levels of
DHEA in relation to DHEAS did not increase during
anti-TNF therapy in patients with RA (32), which indi-
cates that DHEAS-to-DHEA conversion from nonin-
flamed tissue such as fat tissue may be remarkably
higher, which will mask the effects of anti-TNF–induced
restoration of local hormone secretion in inflamed syno-
vial tissue.
Dulos et al demonstrated that TNF stimulates
the conversion of DHEA to the androgen 7-hydroxy-
DHEA in synovial tissue of RA patients and arthritic
animals (Figure 1) (28,29). Other investigators con-
firmed conversion of this particular steroid hormone in
mixed RA synovial cells (30). The 7-hydroxy-DHEA
mediates proinflammatory effects (28,29). One can ex-
pect that TNF neutralization inhibits this unfavorable
steroid conversion, which, together with the above-
mentioned increase of DHEA, would enhance local
androgen concentrations.
Furthermore, TNF stimulates the aromatase-
mediated conversion of androstenedione to estrone and
of testosterone to 17-estradiol in peripheral nontumor
nonendocrine cells (Figure 1 and Table 1) (33,34). Such
stimulation would further reduce the availability of
antiinflammatory androgens in local tissue. In addition,
the increase of estrogens most probably leads to further
conversion into downstream pro-proliferative estrogens
such as 16-hydroxyestrogens or 4-hydroxyestrogens
(35). This is accompanied by a loss of antimitogenic
2-hydroxyestrogens, as demonstrated in patients with
RA and patients with systemic lupus erythematosus
(SLE) (36,37).
In this respect, it is interesting that male patients
with RA seem to profit more from anti-TNF strategies
than do female patients (in Italy, Montecucco CM:
personal communication; in Norway, Kvien TK: per-
sonal communication). Because male patients have ele-
vated levels of circulating androgens in comparison with
female patients, this probably leads to higher local levels
of proinflammatory estrogens in men compared with
women (e.g., 16-hydroxyestrogens or 4-hydroxyestrogens).
Blockade of TNF-induced up-regulation of aromatase
would particularly increase the level of androgens in
male as compared with female patients with RA, and
this can lead to a better clinical outcome in male
patients.
Interestingly, TNF neutralization over several
weeks in patients with RA did not change the ratio of
serum levels of androgens versus estrogens (32). Several
reasons for this obvious discrepancy may exist. First, the
neutralizing capacity of anti-TNF therapy in the target
tissue is inadequate to restore these hormones. Second,
anti-TNF antibodies do not neutralize TNF in the target
tissue but influence other important proinflammatory
immune phenomena such as apoptosis (38). Third, the
amount of adrenal and sex hormones from noninflamed
tissue such as fat tissue may be much higher than
expected, which can mask the effects of anti-TNF–
induced restoration of local hormone secretion in in-
flamed synovial tissue. Fourth, the hormonal dissocia-
tion with an increase in the level of estrogens in relation
Figure 2. The hypothalamus–pituitary gland–liver–muscle axis.
Growth hormone–releasing hormone (GHRH) from the hypothala-
mus stimulates pituitary growth hormone release. Growth hormone
stimulates production of insulin-like growth factor 1 (IGF-1) by the
liver. Liver IGF-1 stimulates muscle growth directly and by inducing
muscular IGF-1 (1). Tumor necrosis factor (TNF) and exogenous
glucocorticoids inhibit the effects of liver IGF-1 and local IGF-1 on
muscle growth (2). TNF and glucocorticoids increase protein degra-
dation in the muscle. Consumption of liver IGF-1 and down-regulation
of local IGF-1 decrease the negative feedback signal to the liver (3). In
patients receiving glucocorticoids, this leads to loss of the negative
feedback signal to the liver and, thus, to an increase in measurable liver
IGF-1 levels in serum. IGF-1 itself inhibits GHRH release (4), which
is also inhibited by endogenous and exogenous glucocorticoids.
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to androgens lasts for considerably longer than 12–16
weeks, as has been observed previously (39). Fifth, in
highly inflamed synovial tissue, TNF is not the sole
modulator of altered estrogen production (Table 1).
This would imply that neutralization of other cytokines
is needed to restore these hormones. Sixth, hormonal
alterations may exist for a very long time before the
outbreak of RA, which has been demonstrated for
serum DHEAS (40). The lack of adequate secretion of
important antiinflammatory hormones such as DHEAS
can be a genetic prerequisite in an individual affected by
RA (40).
The hypothalamus–pituitary gland–liver–muscle axis
A majority of patients with RA experience de-
creased muscle function and loss of body cell mass
(41,42). High levels of TNF in parallel with glucocorti-
coid therapy were thought to be important elements for
these alterations in patients with RA (Figure 2) (43,44).
One key element in maintaining muscle mass is the
presence of insulin-like growth factor 1 (IGF-1), which
promotes muscle growth and suppresses muscle degra-
dation (Figure 2) (45). Glucocorticoid therapy can lead
to IGF-1 resistance (46); such resistance has been dem-
onstrated during glucocorticoid therapy by an increase
in IGF-1 serum levels (46). A very similar phenomenon
exists with respect to insulin resistance (47), and patients
with RA demonstrate insulin resistance (48). TNF neu-
tralization improved insulin resistance (48), and anti-
TNF therapy improves the HOMA (homeostatis model
of assessment) index, which is an indicator of insulin
resistance (Li EK: personal communication). Similarly,
anti-TNF therapy improves glucocorticoid-induced
IGF-1 resistance without influencing myoglobin and
IGF-1–binding proteins 1 and 3 (49). These studies
demonstrate that TNF neutralization exerts positive
effects on insulin and IGF-1 signaling, which is impor-
tant for overcoming decreased muscle function and
reducing cardiovascular risk. These are 2 additional
favorable effects of TNF blockade.
The hypothalamus–autonomic nervous system axis
Several studies demonstrated that patients with
chronic inflammatory diseases have increased tonus of
the sympathetic nervous system (50–53). Increased sym-
pathetic activity is probably closely related to the in-
creased risk of cardiovascular events as observed in
patients with RA (54). Such increased sympathetic tonus
may be a consequence of relatively decreased serum
levels of cortisol in relation to inflammation, because
cooperativity of cortisol and norepinephrine exists on a
molecular level via the -adrenergic receptor signaling
cascade (55,56).
Functional loss of one factor probably up-
regulates the other factor in order to maintain functions
such as blood glucose homeostasis, regulation of the
bronchial lumen, blood pressure control, and others.
Because TNF is relevant for adaptation of the HPA axis,
leading to inadequately low cortisol secretion (see
above), its neutralization may change the increased
sympathetic tonus. In a recent study, we confirmed the
Figure 3. Summary of neuroendocrine alterations in patients with
rheumatoid arthritis. Pink circles indicate the deleterious effects of
tumor necrosis factor (TNF) on several levels of the endocrine and
neuronal supersystems. Double red bars indicate a reduction in the
respective pathway. Pathways of the parasympathetic system are not
shown. GnRH  gonadotropin-releasing hormone; CRH 
corticotropin-releasing hormone; GH  growth hormone; LH 
luteinizing hormone; FSH  follicle-stimulating hormone; ACTH 
adrenocorticotropic hormone; AG  adrenal gland; IGF-1  insulin-
like growth factor 1; DHEA  dehydroepiandrosterone; ASD 
androstenedione.
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increased sympathetic tonus in patients with RA and
also in those with SLE, which was accompanied by a
relatively normal tonus of the HPA axis (called “uncou-
pling of the HPA and HANS axis” during chronic
inflammation, because an increase in the tonus of both
axes can be expected during acute inflammation) (57).
Interestingly, 12 weeks of anti-TNF therapy only slightly
decreased the sympathetic tonus as measured by plasma
neuropeptide Y levels. Thus, it seems that uncoupling
remains for a long time, and it appears that TNF is not
the sole and main factor responsible for this phenome-
non (i.e., other circulating cytokines are also responsi-
ble).
It should be mentioned that increased tonus of
the sympathetic nervous system probably would not lead
to an increased number of local sympathetic neurotrans-
mitters in the inflamed joint, because sympathetic nerve
fibers are lost (58). In such a situation, local concentra-
tions of sympathetic neurotransmitters are too low to
exert antiinflammatory effects via -adrenoceptors (for
review, see ref. 59). Whether long-term TNF neutraliza-
tion increases the density of sympathetic nerve fibers in
the synovium is presently not known.
The central nervous system
It is well known that patients with chronic inflam-
matory diseases show signs of chronic fatigue and de-
pression (60–63). In recent years, it has been demon-
strated that circulating cytokines and activation of
sensory nerve fibers in the periphery are most probably
involved in these central nervous system alterations (64).
Cytokines induce so-called sickness behavior (64). The
injection of lipopolysaccharide into healthy controls
leads to a significant increase in depression scores (65).
Further findings demonstrated that elevated cytokine
concentrations deteriorate sleep and declarative mem-
ory (66). TNF is an important mediator of these changes
during the course of chronic inflammatory diseases.
Indeed, it has been demonstrated that TNF neutraliza-
tion decreased sleepiness in patients with sleep apnea
(67). In addition, as occurs with patients receiving other
immunosuppressive drugs, patients with RA who were
receiving anti-TNF antibody therapy demonstrated a
marked reduction in fatigue scores (60), and they expe-
rienced an improved sense of well-being and decreased
joint pain (68). These findings show that elevated levels
of circulating TNF have an important impact on brain
function.
Conclusion
Numerous hormonal and neuronal pathways are
severely altered in patients with RA and those with other
chronic diseases (see Figure 3). At several locations,
TNF is an important mediator of these alterations
(Figure 3). Because TNF is able to modulate many
neuroendocrine pathways, most often leading to unfa-
vorable changes of these axes (in the direction of an
overall proinflammatory situation), its neutralization is
of critical importance to normalize these pathways.
Normalization of neuroendocrine axes by anti-TNF
therapy supports the antiinflammatory environment and
readjusts the milieu interne. Thus, anti-TNF therapy is
not only immunosuppressive by inhibiting TNF effects,
but it is also favorable in that it restores hormonal
pathways, leading to a more normal situation. The
described effects of TNF-neutralizing therapies on al-
tered hormonal and neuronal supersystems is an alter-
native mode of antiinflammatory action. It might well be
that neutralization of other cytokines such as IL-1,
IFN, or IL-6 can have comparable effects, because
these cytokines influence neuroendocrine axes in a
similar manner (Table 1). Future studies with cytokine-
neutralizing strategies should include hormonal readout
parameters in order to further characterize restoration
of neuroendocrine axes.
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